z-logo
Premium
A new model to determine Optimal Exposure to Tacrolimus and Mycophenolate Mofetil after renal transplantation
Author(s) -
Pankewycz Oleh,
Onan Engin,
Rucker Dane,
Wang Dongliang,
Gruessner Angelika,
Gruessner Rainer,
Laftavi Mark R.
Publication year - 2020
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13893
Subject(s) - medicine , mycophenolic acid , tacrolimus , therapeutic drug monitoring , dosing , mycophenolate , transplantation , area under the curve , kidney transplantation , pharmacokinetics , urology , trough level , gastroenterology , pharmacology
Background Drug dosing for Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) after kidney transplantation remains challenging. Therapeutic drug monitoring (TDM) offers a means to individualize drug dosing and improve outcomes. Methods In this observational study, patients having mycophenolic acid (MPA) exposure assessed by limited sampling strategy (LSS) within the first 6 months were included and followed for 1 year. Results A total of 113 clinical events occurring in 110 patients were classified into 3 groups: Group 1 Stable (n = 34), Group 2 Over drug exposed (n = 64) having infections or drug toxicity and Group 3 Under drug exposed (n = 15) developing rejection or de novo donor‐specific alloantibodies. Although TAC levels, MMF dose, MPA, and MPA Glucuronide (MPAG) exposure, expressed as area under curve (AUC), individually failed to predict outcomes, a scoring model incorporating all 3 drug levels TAC TDM × (MPA AUC + MPAG/10 AUC) correctly classified outcomes. A score over 1071 had a sensitivity and specificity of 0.94 (95% CI 0.56‐0.83) and 0.84 (95% CI 0.69‐0.89) for over exposure. A score below 625 had a sensitivity and specificity of 0.76 (95% CI 0.53‐0.93) and 0.80 (95% CI 0.41‐0.70) for under exposure. Conclusions This integrated model of assessing TAC and MMF exposure may facilitate individualized therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here